Collegium Pharmaceutical (COLL)

• Market cap: $1.05B
• 1 day: 1%
• 5 days: 0.33%
• 1 month: -6.77%
• 3 months: 4.53%
• 6 months: 22.91%
• Year to date: 16%
• 1 year: -15.58%
• 5 years: 60.05%
• 10 years: 72.34%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Employees: 357